Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation

  • Authors:
    • Se‑Uk Kwon
    • Ji‑Yoon Cha
    • Hoon‑Yeon Lee
    • Mingjie Xin
    • Su‑Jeong Ji
    • Dae‑Ki Kim
    • Do‑Sim Park
    • Mi‑Kyung Pyo
    • Young‑Mi Lee
  • View Affiliations

  • Published online on: February 9, 2015     https://doi.org/10.3892/mmr.2015.3319
  • Pages: 4255-4261
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Euphorbia maculata (EM) is a traditionally used antidiarrheal, antibacterial, antifungal and antioxidant agent. However, the effects of EM on platelet activity remain to be elucidated. Therefore, the present study investigated the antiplatelet effect of various EM extract fractions on platelet aggregation in rats. The antiplatelet activity of the EM fractions on collagen or adenosine diphosphate (ADP)‑induced platelet aggregation was evaluated in vitro and ex vivo. Thromboxane B2 (TXB2) formation, rat‑tail bleeding time and coagulation time were also measured. Among the fractions, the chloroform fraction of EM (CFEM) significantly inhibited ADP‑induced platelet aggregation in vitro. Furthermore, oral administration of 50 mg/kg CFEM to rats significantly reduced ADP‑induced platelet aggregation without increasing the tail bleeding time or coagulation time. In addition, EM significantly inhibited the level of TXB2 formation in a dose‑dependent manner. These results suggest that CFEM exhibits antiplatelet activity, without causing bleeding, via the suppression of TXB2 formation. CFEM may be a type of food which has the potential for preventing cardiovascular disease.

Introduction

Platelets are critical in hemostasis and thrombus formation (1,2). When blood vessels are damaged, diverse types of agonists, including collagen, adenosine diphosphate (ADP), arachidonic acid (AA) and thrombin, are promptly released and induce platelet aggregation (3,4). However, abnormal platelet activation may cause cardiovascular diseases (CVDs), including ischemic heart disease, thrombosis, stroke, myocardial infarction and atherosclerosis, which are major diseases responsible for human mortality worldwide (5,6). Thus, reducing platelet aggregation is important for limiting atherosclerosis and CVD (7). Consequently, numerous types of drugs, including antiplatelet, anticoagulant and fibrinolytic agents, have been developed to moderate or prevent thrombosis (8).

A number of anti-thrombotic drugs have been developed and used clinically. Acetylsalicylic acid (ASA), which is a direct cyclooxygenase (COX) inhibitor, is generally used to suppress platelet aggregation (9). However, continuous administration of ASA can induce resistance or side effects, including headache, vomiting, gastric ulceration and abdominal pain in numerous patients (10-13). Therefore, studies have been investigating naturally derived antiplatelet agents with a reduced risk of side effects (14-19).

Euphorbia maculata (EM) is an annual plant, which belongs to the family Euphorbiaceae. EM is grown worldwide, including in East Africa, South America, Korea, Japan and China (20). The antidiarrheal, antibacterial, antifungal and antioxidant activities of this plant have been reported, however, to the best of our knowledge, studies on the antiplatelet effect of EM have not yet been conducted (20-23).

In the present study, the antiplatelet activities of EM fractions were investigated in vitro and ex vivo.

Materials and methods

Materials

Euphorbia maculata (spotted spurge; EM) was provided by Wonkwang Herb Inc. (Jeonbuk, Korea). Collagen, adenosine diphosphate (ADP), AA and thrombin were obtained from Chrono-Log (Havertown, PA, USA). Trisodium citrate tubes were purchased from Greiner Bio-One (Frickenhausen, Germany). ASA, ketamine HCl, xylazine HCl, β-nicotinamide adenine dinucleotide (β-NADH), ethylenediaminetetraacetic acid (EDTA), indomethacin, pyruvic acid and sodium chloride were purchased from Sigma-Aldrich (St. Louis, MO, USA). A thromboxane B2 (TXB2) enzyme immunoassay (EIA) kit was purchased from Enzo Life Sciences (Farmingdale, N Y, USA).

Animals

Male Sprague Dawley (SD) rats weighing 250-280 g were obtained from Samtaco Co., Ltd. (Osan, Korea). All the animals were maintained under standard laboratory conditions and allowed free access to food and water ad libitum. The specific pathogen-free animal room was maintained at a temperature of 23±2˚C with a humidity of 60±5% in a 12 h light/dark cycle. All animal experimentation protocols used in the present study were approved by the Animal Experiments Committee of Wonkwang University (Iksan, Korea).

Preparation of EM fractions

The aerial parts of Euphorbia maculata (100 g) were reflux extracted with ethanol at 80˚C for 2 h. Following filtration, the residue was re-extracted twice as described above. The combined filtrate was evaporated and lyophilized to obtain the crude extract. The crude extract was further fractionated using chloroform, ethyl acetate, butanol and distilled water. The fractionation scheme is shown in Fig. 1.

Lactate dehydrogenase (LDH) release assay

The cytotoxic activity of the EM fractions was determined by measuring LDH release from the platelets, as described previously with minor modifications (24,25). Briefly, male SD rats were anesthetized by intraperitoneal injection with a mixture of ketamine HCl (60 mg/kg) and xylazine HCl (10 mg/kg) and blood was collected from the abdominal aorta using a trisodium citrate tube (3.8%, 1:9, v/v). The collected blood was centrifuged at 120 × g for 10 min at 37˚C to prepare rat platelet rich plasma (PRP) and the remaining blood was further centrifuged at 200 × g for 10 min at 37˚C to obtain platelet-poor plasma (PPP). The platelet count was adjusted to 3×108 platelets/ml using PPP as a diluent for use in the LDH release assay.

PRP was incubated at 37˚C for 10 min in the presence or absence of the EM fractions and centrifuged at 12,000 × g for 2 min. To measure LDH leakage, 50 μl aliquots of PRP were collected and mixed with 200 μl of β-NADH solution (0.03% β-NADH in phosphate buffer) and 50 μl of pyruvate solution (22.7 mM) at room temperature. The reductions in absorbance due to the conversion of NADH to NAD+ were measured using a spectrophotometer (SpectraMax M2; Molecular Devices, Sunnyvale, CA, USA) at a wavelength of 340 nm. LDH release was measured in platelets lysed with 0.2% Triton X-100 and expressed as a percentage of the total enzyme activity.

In vitro platelet aggregation assay

Male SD rats were anesthetized by intraperitoneal injection with a mixture of ketamine HCl and xylazine HCl and blood was collected from the abdominal aortas using trisodium citrate tubes (3.8%, 1:9, v/v). The collected blood was centrifuged at 120 × g for 10 min to obtain PRP and PPP. The platelet count was adjusted to 3×108 platelets/ml for the platelet aggregation assay.

Platelet aggregation was measured using turbidimetric methods with minor modifications (26,27). Briefly, PRP was preincubated with or without various concentrations of the EM fractions for 5 min at 37˚C. Platelet aggregation was induced by adding 5 μM ADP and 3 μg/ml collagen. The quantity of light transmitted through the sample, as a measure of platelet aggregation, was observed for a further 5 min at 37˚C using an aggregometer (Model 700; Chrono-log).

Ex vivo platelet aggregation assay

Male SD rats were divided randomly into three groups of 10 rats each and orally administered water (normal), aspirin (20 mg/kg) or CFEM (2, 10 and 50 mg/kg) 2 h prior to sacrifice. Rats were anesthetized with a mixture of ketamine HCl and xylazine HCl by intraperitoneal injection, and blood was collected from the abdominal aortas using trisodium citrate tubes. The collected blood was then centrifuged to obtain PRP and PPP. The platelet aggregation assay was performed as described above.

Ex vivo anticoagulant assay

Prothrombin time (PT) and activated partial thromboplastin time (aPTT) was measured as previously described (27). The coagulation assay was performed using PPP from CFEM-treated rats and measured using a coagulometer (Coatron M4; Teco Medical Instruments GmbH, Neufahrn, Germany). Determination of aPTT and PT were performed according to the manufacturer’s instructions. For the PT assay, 25 μl of PPP was incubated for 1.5 min at 37˚C. The assay reaction was started by adding 50 μl of PT reagent and observed for 3 min. For the aPTT assay, 25 μl of PPP was preincubated with 25 μl of the aPTT reagent for 5 min at 37˚C. Subsequently, the assay reaction was initiated by adding 25 μl of 25 mM CaCl2 and observed for 5 min at 37˚C. The clotting time was determined as being the time required to achieve a 50% change in the scattered light transmission as measured at 660 nm.

Tail bleeding time

Bleeding time was measured as described with minor modifications (28). Rats were anesthetized with ketamine and xylazine. The tail was transected 5 mm from the tip and promptly immersed in 0.9% saline at 37˚C. Bleeding time was defined as the time required for the blood flow to stop for at least 30 sec. If bleeding continued for >30 min, the assay was halted and the bleeding time recorded as 30 min for statistical analysis.

Measurement of TXB2 formation

PRP (3×108 platelets/ml) was preincubated with various concentrations of CFEM for 5 min and 5 μM ADP was added. Subsequently, 50 mM indomethacin and 2 mM EDTA were mixed to stop the reaction. The aliquots were centrifuged at 12,000 × g for 10 min and the supernatant was collected. TXB2 formation was measured using an EIA kit according to the manufacturer’s instructions.

Statistical analysis

The results are presented as the mean ± standard deviation. Comparisons between groups were performed using Student’s t-test and all statistical analyses were performed using SPSS 22.0 software (International Business Machines, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of EM fractions on LDH release

The cytotoxicity of the EM fractions on rat platelets was investigated by measuring LDH release. As shown in Fig. 2, up to 100 μg/ml of EM extract did not induce LDH release from the platelets. This suggested that the EM fractions did not affect platelet viability or induce platelet lysis in rat plasma.

Effect of EM fractions on platelet aggregation

As shown in Fig. 3, none of the EM fractions affected collagen-induced platelet aggregation. However, CFEM significantly reduced ADP-induced platelet aggregation. When PRP was stimulated by ADP, the aggregation rate was significantly increased from 1.4±0.71 to 68.5±2.12%. Furthermore, CFEM decreased ADP-induced platelet aggregation by 66.4±3.1, 570±4.7 and 50.2±1.4% at 10, 30 and 100 μg/ml (Fig. 4).

Effect of CFEM on platelet aggregation in rats

Since CFEM was an effective antiplatelet agent against ADP-induced platelet aggregation in vitro, the effects of CFEM were assessed in an animal model of platelet aggregation induced by ADP. As shown in Fig. 5, the aggregation rate of the untreated rats was 71.73±4.65%, but was reduced by CFEM treatment. In rats treated with 2, 10 and 50 mg/kg of CFEM, ADP-induced platelet aggregation was decreased to 67.33±5.20, 61.50±2.59 and 51.25±1.13%, respectively.

Effect of CFEM on tail bleeding time in rats

Fig. 6 shows the effect of CFEM on bleeding time in rats. The bleeding time of untreated rats was 824±120.32 sec and was significantly increased to 1557±165.61 sec in aspirin-treated rats. The tail bleeding time of rats treated with 2, 10 and 50 mg/kg CFEM was 901±5756, 1020±120.79 and 1044±86.53 sec, respectively.

Effect of CFEM on coagulation time in rats

As shown in Table I, CFEM did not extend the coagulation time in rats. The PT of untreated rats was 24.4±0.45 sec and the coagulation times of rats treated with 2, 10 and 50 mg/kg of CFEM were 245±0.34, 25.0±0.44 and 249±0.52 sec, respectively. In addition, the aPTT of CFEM-treated rats was 18.8±1.07, 19.3±074 and 18.6±0.52 sec, which was not significantly different compared with the untreated rats (18.9±0.63 sec).

Table I

Effect of CFEM on coagulation time in rats.

Table I

Effect of CFEM on coagulation time in rats.

GroupDose (mg/kg)PT (sec)aPTT (sec)
Normal24.4±0.4518.9±0.63
Aspirin2025.6±0.9218.7±0.98
CFEM224.5±0.3418.8±1.07
1025.0±0.4419.3±074
5024.9±0.5218.6±0.52

[i] Data are expressed as the mean ± standard deviation (n=10). CFEM, chloroform fraction of EM; PT, prothrombin time; aPTT, activated partial thromboplastin time.

Effect of CFEM on TXB2 formation

Fig. 7 shows the effect of CFEM on TXB2 formation. ADP increased the level of generated TXB2 to approximately three times that of the control and was reduced in a dose-dependent manner by CFEM. ADP-induced PRP produced 24.64±0.319 ng/ml of TXB2 and 10, 30 and 100 μg/ml of CFEM decreased TXB2 to 23.80±0.647, 21.48±1.337 and 13.73±0.432 ng/ml, respectively.

Discussion

In the present study, the inhibitory effect of our EM fractions on collagen- and ADP-induced platelet aggregation in rat plasma was evaluated.

Platelet activation and aggregation have pivotal roles in the pathogenesis of thrombotic complications, including atherosclerosis, myocardial infarction, thromboembolism and other vascular diseases (2,29). Thus, reducing platelet hyperactivation and aggregation is directly connected to the treatment of thrombotic disease in the clinic (30). Anti-coagulating agents are widely used to effectively inhibit platelet aggregation and prevent cardiovascular events. However, continuous use of these agents is prohibited due to adverse effects, including an increased likelihood of a bleeding event (9,13). For this reason, there has been several attempts to overcome these limitations in atherothrombosis treatment and substitute antiplatelet agents, including ADP-receptor agonists, are recommended, as has been demonstrated in numerous clinical trials (31).

In the resting state, platelets freely flow through blood vessels. However, when platelets adhere to damaged vessels, platelet activation and aggregation promptly occur. This process is stimulated by endogenous agonists, including ADP, thrombin, collagen, serotonin, TXA2 and AA (32). Although weak, ADP is the most important mediator among these, as it causes alterations in platelet shape, aggregation and TXA2 secretion (33). ADP, along with adenosine triphosphate and serotonin, is stored in dense granules inside of platelets and is secreted at sites of injury by platelet activation. The released ADP binds to the purinergic receptors P2Y1 and P2Y12. Activation of the P2Y1 receptor pathway triggers intracellular calcium mobilization and alters platelet shape, while P2Y12 receptor activation inhibits adenylyl cyclase-dependent cyclic adenosine monophosphate generation and prolongs platelet aggregation (34). The antiplatelet agents currently in use (e.g. clopidogrel, ticagrelor and prasugrel) effectively reduce platelet aggregation by inhibiting ADP-P2Y12 receptor binding (35-38). In the present study, CFEM reduced collagen and ADP-induced platelet aggregation in vitro and CFEM-administered rats decreased ADP-triggered platelet. aggregation in a dose-dependent manner ex vivo. These results suggest that CFEM exerts antiplatelet activity particularly on ADP-induced platelet aggregation.

Normal homeostasis relies on the balance between procoagulation and anticoagulant activities (39). When these activities favor anticoagulant effects or procoagulation effects, continuous bleeding is likely to occur (40). The bleeding time, as determined using the tail-transection assay is a well-recognized index of hemostasis and is used to investigate clinically important adverse effects of anticoagulants (41,42). CFEM did not demonstrate significant alterations in bleeding time, which is the main adverse effect of antiplatelet treatment. Thus, this suggested that CFEM treatment is unlikely to produce uncontrollable bleeding.

Coagulation is the consequence of a complex process that occurs by intrinsic, extrinsic and common pathways. Thus, blood coagulation is highly associated with platelet interactions with coagulation factors and blood vessels (43). When measuring coagulation, the PT assay is used to evaluate the extrinsic pathway and the aPTT assay measures the activation of the intrinsic pathway. These tests are recognized as useful methods to confirm bleeding risk and the potential for thrombotic adverse effects (44,45). The anticoagulant activities of CFEM were examined using the coagulation assays and CFEM did not affect PT and aPTT.

A TXA2-mediated pathway is also important in antiplatelet treatments. During platelet aggregation, AA is liberated from the platelet plasma membrane and promptly metabolized to TXA2 via the COX and thromboxane A2 synthase pathway (46). TXA2 acts to amplify the intracellular signals for platelet aggregation, vasoconstriction and recruitment of platelets (47). In addition, P2Y receptor activation, in turn, stimulates TXA2 receptor activation, which triggers ADP secretion (48,49). This suggests that TXA2 formation is closely associated with ADP-induced platelet aggregation and agents that reduce TXA2 secretion may be therapeutically useful in platelet-associated CVDs. However, TXA2 has an extremely short half-life and is unstable; therefore, TXB2 levels are assessed as a measure of TXA2 formation (50). CFEM significantly decreased the level of TXB2 suggesting that suppression of TXB2 formation is associated, in part, to the inhibitory effect of CFEM on platelet aggregation.

In conclusion, CFEM inhibits ADP-induced platelet aggregation by reducing TXB2 formation, without affecting bleeding time or the coagulation pathways. These results suggest that CFEM possesses antiplatelet activity and may be a useful therapeutic for thrombotic disease.

Acknowledgments

This study was supported by grants from Wonkwang University in 2012.

References

1 

Packham MA and Mustard JF: The role of platelets in the development and complication of atherosclerosis. Semin Hematol. 23:8–26. 1986.PubMed/NCBI

2 

Ruggeri ZM: Mechanisms initiating platelet thrombus formation. Thromb Haemost. 78:611–616. 1997.PubMed/NCBI

3 

Ruggeri ZM: Platelets in atherothrombosis. Nat Med. 8:1227–1234. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Brass LF: Thrombin and platelet activation. Chest. 124(Suppl 3): 18S–25S. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Lindholm LH and Mendis S: Prevention of cardiovascular disease in developing countries. Lancet. 370:720–722. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Furie B and Furie BC: Mechanisms of thrombus formation. N Engl J Med. 359:938–949. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Gross PL and Weitz JI: New antithrombotic drugs. Clin Pharmacol Ther. 86:139–146. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Collins B and Hollidge C: Antithrombotic drug market. Nat Rev Drug Discov. 2:11–12. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Gaglia MA Jr, Manoukian SV and Waksman R: Novel antiplatelet therapy. Am Heart J. 160:595–604. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Fong J, Cheng-Ching E, Hussain MS, Katzan I and Gupta R: Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 20:227–230. 2011. View Article : Google Scholar

11 

Fitzgerald R and Pirmohamed M: Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 130:213–225. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Barrett NE, Holbrook L, Jones S, et al: Future innovations in antiplatelet therapies. Br J Pharmacol. 154:918–939. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Jackson SP and Schoenwaelder SM: Antiplatelet therapy: in search of the ‘magic bullet’. Nat Rev Drug Discov. 2:775–789. 2003. View Article : Google Scholar : PubMed/NCBI

14 

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 49:1505–1516. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Tsai IL, Lin WY, Teng CM, et al: Coumarins and antiplatelet constituents from the root bark of Zanthoxylum schinifolium. Planta Med. 66:618–623. 2000. View Article : Google Scholar : PubMed/NCBI

16 

Ballabeni V, Tognolini M, Bertoni S, et al: Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam) Kosterm (Lauraceae) calices from Amazonian Ecuador. Pharmacol Res. 55:23–30. 2007. View Article : Google Scholar

17 

Seo EJ, Lee DU, Kwak JH, et al: Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone. J Ethnopharmacol. 135:48–54. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Fuentes E and Palomo I: Relationship between platelet PPARs, cAMP levels, and P-Selectin expression: Antiplatelet activity of natural products. Evid Based Complement Alternat Med. 2013:8617862013. View Article : Google Scholar : PubMed/NCBI

19 

Fuentes E, Caballero J, Alarcón M, Rojas A and Palomo I: Chlorogenic acid inhibits human platelet activation and thrombus formation. PLoS One. 9:e906992014. View Article : Google Scholar : PubMed/NCBI

20 

Yoshiaki A, Keita K, Tsutomu H, et al: Four new hydrolysable tannins and an acylated flavonol glycoside from Euphorbia maculate. Can J Chem. 75:727–733. 1997. View Article : Google Scholar

21 

Cao X, Wang W, Zhou L, Cui X and Song X: Comparison on mass fraction of total flavonoids and tannin of three kinds of herba Euphorbiae Humifusae and their antibacaterial activity in vitro. Acta Agriculturae Boreali-Occidentalis Sinica. 21:184–188. 2012.

22 

Kuerbannisha M, Zulipiya T, Gulina D, Xieraili T and Silafu A: Determination of rutin and quercitrin in the antifungal extract from Euphorbia maculate. Lishizhen Medicine and Materia Medica Research. 22:2584–2585. 2011.

23 

Liu S, Jiang D and Li L: Research on the total flavonoids’ content and antioxidant activity of Euphorbia maculata and Euphorbia humifusae. J Hunan Agr U Nat Sci. 33:287–288. 2007.

24 

Lee BK, Lee DH, Park S, et al: Effects of KR-33028, a novel Na+/H+ exchanger-1 inhibitor, on glutamate-induced neuronal cell death and ischemia-induced cerebral infarct. Brain Res. 1248:22–30. 2009. View Article : Google Scholar

25 

Ryu KH, Han HY, Lee SY, et al: Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thromb Res. 124:328–334. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Mustard JF, Perry DW, Ardlie NG and Packham MA: Preparation of suspensions of washed platelets from humans. Br J Haematol. 22:193–204. 1972. View Article : Google Scholar : PubMed/NCBI

27 

Lee BJ, Jo IY, Bu Y, et al: Antiplatelet effect of Spatholobus suberectus via inhibition of glycoprotein IIb/IIIa receptor. J Ethnopharmacol. 134:460–467. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Cho J, Furie BC, Coughlin SR and Furie B: A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest. 118:1123–1131. 2008.PubMed/NCBI

29 

Majid A, Delanty N and Kantor J: Antiplatelet agents for secondary prevention of ischemic stroke. Ann Pharmacother. 35:1241–1247. 2001. View Article : Google Scholar : PubMed/NCBI

30 

Wijns W, Kolh P, Danchin N, et al: Guidelines on myocardial revascularization. Eur Heart J. 31:2501–2555. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Albers GW and Amarenco P: Combination therapy with clopidogrel and aspirin: can the cure results be extrapolated to cerebrovascular patients? Stroke. 32:2948–2949. 2001. View Article : Google Scholar : PubMed/NCBI

32 

Jin YR, Hwang KA, Cho MR, et al: Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative. Vasc Pharmcol. 41:35–41. 2004. View Article : Google Scholar

33 

Kunapuli SP, Dorsam RT, Kim S and Quinton TM: Platelet purinergic receptors. Curr Opin Pharmacol. 3:175–180. 2003. View Article : Google Scholar : PubMed/NCBI

34 

Hollopeter G, Jantzen HM, Vincent D, Li G, England L and Ramakrishnan V: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 409:202–207. 2001. View Article : Google Scholar : PubMed/NCBI

35 

Gachet C: P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 99:466–472. 2008.PubMed/NCBI

36 

Cattaneo M: Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther. 5:45–55. 2007. View Article : Google Scholar

37 

Cattaneo M: New P2Y12 blockers. J Thromb Haemost. 7(Suppl 1): 262–265. 2009. View Article : Google Scholar : PubMed/NCBI

38 

Jakubowski JA, Winters KJ, Naganuma H and Wallentin L: Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 25:357–374. 2007. View Article : Google Scholar : PubMed/NCBI

39 

Akiyama H, Kudo S and Shimizu T: The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung. 35:1124–1132. 1985.PubMed/NCBI

40 

Li Y and Wang N: Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. J Ethnopharmacol. 128:623–628. 2010. View Article : Google Scholar : PubMed/NCBI

41 

Renné T, Nieswandt B and Gailani D: The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cell Mol Dis. 36:148–151. 2006. View Article : Google Scholar

42 

Azevedo AP, Farias JC, Costa GC, et al: Anti-thrombotic effect of chronic oral treatment with Orbignya phalerata Mart. J Ethnopharmacol. 111:155–159. 2007. View Article : Google Scholar

43 

Mann KG: Thrombin: can’t live without it; probably die from it. Chest. 124(Suppl 3): 1S–3S. 2003. View Article : Google Scholar

44 

Jennings LK: Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 102:248–257. 2009.PubMed/NCBI

45 

Mitchell MD, Bibby JG, Hicks BR, et al: Thromboxane B2 and human parturition: concentrations in the plasma and production in vitro. J Endocrinol. 78:435–441. 1978. View Article : Google Scholar : PubMed/NCBI

46 

Storey RF, Judge HM, Wilcox RG and Heptinstall S: Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 88:488–494. 2002.PubMed/NCBI

47 

Barton JF, Hardy AR, Poole AW and Mundell SJ: Reciprocal regulation of platelet responses to P2Y and thromboxane receptor activation. J Thromb Haemost. 6:534–543. 2008. View Article : Google Scholar

48 

Viinikka L and Ylikorkala O: Measurement of thromboxane B2 in human plasma or serum by radioimmunoassay. Prostaglandins. 20:759–766. 1980. View Article : Google Scholar : PubMed/NCBI

49 

Plow EF and Ginsberg MH: Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb. 9:117–156. 1989.

50 

Helft G, Gilard M, Feuvre Le C and Zaman AG: Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication or anticoagulation. Nat Clin Pract Cardiovasc Med. 3:673–680. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June-2015
Volume 11 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kwon SU, Cha JY, Lee HY, Xin M, Ji SJ, Kim DK, Park DS, Pyo MK and Lee YM: Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation. Mol Med Rep 11: 4255-4261, 2015
APA
Kwon, S., Cha, J., Lee, H., Xin, M., Ji, S., Kim, D. ... Lee, Y. (2015). Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation. Molecular Medicine Reports, 11, 4255-4261. https://doi.org/10.3892/mmr.2015.3319
MLA
Kwon, S., Cha, J., Lee, H., Xin, M., Ji, S., Kim, D., Park, D., Pyo, M., Lee, Y."Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation". Molecular Medicine Reports 11.6 (2015): 4255-4261.
Chicago
Kwon, S., Cha, J., Lee, H., Xin, M., Ji, S., Kim, D., Park, D., Pyo, M., Lee, Y."Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation". Molecular Medicine Reports 11, no. 6 (2015): 4255-4261. https://doi.org/10.3892/mmr.2015.3319